News Sentiment

FHTX sentiment intelligence

Foghorn Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.95 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+12.3% over one week, +42.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

(FHTX) Movement Within Algorithmic Entry Frameworks

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 12.3% Price confirming higher
Trend fit Trend inactive 42.3% over four weeks
Fair value 7.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 37
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 12
www.marketscreener.com 4
TradingKey 4
simplywall.st 4
TradingView 3
Moomoo 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 20
Analyst action 4
Capital return 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Stock Traders Daily Direct company coverage

(FHTX) Movement Within Algorithmic Entry Frameworks

The article analyzes Foghorn Therapeutics Inc. (NASDAQ: FHTX) using algorithmic frameworks, noting conflicting sentiment across horizons and a mid-channel oscillation pattern. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—alon

Tone
Negative 38/100
Event
Market update
Published
15 Jul 2026 09:11
Source
Stock Traders Daily
Finviz Direct company coverage

FHTX - Foghorn Therapeutics Inc Options

This article provides comprehensive financial data for Foghorn Therapeutics Inc. (FHTX), including its last close price, market capitalization, key financial ratios, EPS and sales growth rates, insider and institutional ownership, and performance metrics over various periods. It

Tone
Negative 41/100
Event
Earnings
Published
06 Jul 2026 14:11
Source
Finviz
Finviz Direct company coverage

FHTX - Foghorn Therapeutics Inc Dividends

This article provides a comprehensive financial overview of Foghorn Therapeutics Inc. (FHTX), including its current stock performance, key financial metrics, insider and institutional ownership, and various performance indicators. It highlights the company's valuation, profitabil

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 05:39
Source
Finviz
Stock Titan Direct company coverage

FHTX SEC Filings - Foghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive overview of Foghorn Therapeutics (FHTX) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights recent filings such as an investor presentation from September 2025

Tone
Negative 38/100
Event
Earnings
Published
03 Jul 2026 22:10
Source
Stock Titan
Market source Direct company coverage

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?

Foghorn Therapeutics (FHTX) saw its shares jump 5.8% due to impressive trading volume and growing investor confidence linked to progress in its pipeline candidates for cancer treatments. The company is expected to report a quarterly loss of $0.23 per share and revenues of $8.12 m

Tone
Positive 67/100
Event
Market update
Published
03 Jul 2026 12:10
Source
Market source
marketscreener.com Direct company coverage

Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell 3000E Value Benchmark

Foghorn Therapeutics Inc. (NasdaqGM:FHTX) has been removed from the Russell 3000E Value Benchmark, according to an update on June 28, 2026. This news follows several other index removals for the company, including the Russell 2000 Value and Russell Microcap Value Benchmarks aroun

Tone
Negative 34/100
Event
Market update
Published
30 Jun 2026 16:42
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Benchmark Index

Foghorn Therapeutics Inc. (NasdaqGM: FHTX) has been removed from the Russell Microcap Value Benchmark Index. The article also provides a company profile, financial data, analyst consensus, and a history of recent news related to Foghorn Therapeutics, including its presentations a

Tone
Negative 36/100
Event
Analyst action
Published
29 Jun 2026 13:39
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 2000 Value Benchmark

Foghorn Therapeutics Inc. (NasdaqGM: FHTX) has been removed from the Russell 2000 Value Benchmark Index. This news follows previous reports of the company presenting at the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026 and reporting its first-quarter earning

Tone
Negative 37/100
Event
Market update
Published
29 Jun 2026 11:26
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Small Cap Comp Value Benchmark

Foghorn Therapeutics Inc. (NasdaqGM:FHTX) has been removed from the Russell Small Cap Comp Value Benchmark. This news follows several other announcements regarding the company's removal from various Russell indices, including the Russell 2000 Value, Russell Microcap Value, Russel

Tone
Negative 37/100
Event
Market update
Published
29 Jun 2026 00:13
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 3000 Value Benchmark

Foghorn Therapeutics Inc. (NasdaqGM: FHTX) has been removed from the Russell 3000 Value Benchmark, according to an announcement published on June 28, 2026. This exclusion follows its removal from several other Russell indices, including the Russell 2000 Value, Microcap Value, 300

Tone
Negative 19/100
Event
Market update
Published
28 Jun 2026 00:13
Source
www.marketscreener.com
Barchart.com Direct company coverage

Soft Tissue Sarcoma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings

DelveInsight's "Soft Tissue Sarcoma Pipeline Insight, 2026" report highlights that over 70 companies are developing more than 75 therapies for Soft Tissue Sarcoma, covering various clinical development stages from pre-clinical to marketed phases. The report details emerging thera

Tone
Positive 67/100
Event
Market update
Published
27 Jun 2026 11:41
Source
Barchart.com
TradingView Direct company coverage

Foghorn Therapeutics, Inc. Actuals & Estimates (NASDAQ:FHTX)

This article provides an overview of Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial results, such as recent earnings and revenue, upcoming earnings date, market cap

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 10:09
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Foghorn Therapeutics Inc For: 25 June By Investing.com

This article from Investing.com reports the filing of a Form 4 for Foghorn Therapeutics Inc. on June 25. A Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders, such as officers, directors, or beneficial owners, to report changes i

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 22:40
Source
Investing.com Nigeria
TradingView Direct company coverage

FHTX Forecast — Price Target — Prediction for 2027

This article provides a forecast for Foghorn Therapeutics Inc. (FHTX) stock, including analyst price targets, ratings, and financial performance data. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports,

Tone
Negative 38/100
Event
Analyst action
Published
25 Jun 2026 22:40
Source
TradingView
Stock Titan Direct company coverage

Foghorn Therapeutics (FHTX) director Lynne Parshall awarded 28,000 stock options

Lynne Parshall, a director at Foghorn Therapeutics Inc. (FHTX), was granted 28,000 stock options with an exercise price of $4.08 per share, expiring on June 23, 2036. These options will fully vest on the first anniversary of the grant date, contingent on her continued service on

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Foghorn Therapeutics (FHTX) director granted 28,000 stock options at $4.08 strike

Foghorn Therapeutics director Scott Biller was granted 28,000 stock options with an exercise price of $4.08 per share as compensation. These options will vest in full on the first anniversary of the grant date, provided he continues to serve on the board. Following this grant, Bi

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Director at Foghorn Therapeutics (FHTX) receives 28,000 stock options

Foghorn Therapeutics (FHTX) director Neil Gallagher was granted 28,000 stock options with an exercise price of $4.08 per share. These options are a compensation-related award and will vest in full on the first anniversary of the grant date, provided Gallagher continues his servic

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Foghorn Therapeutics (FHTX) director receives stock options for 28,000 shares

Foghorn Therapeutics director Thomas J. Lynch Jr. was granted stock options for 28,000 shares of common stock with an exercise price of $4.08 per share. These options are set to vest on the first anniversary of the grant date, conditional on his continued service on the board, an

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Director Ian F. Smith receives 28,000 Foghorn Therapeutics (FHTX) stock options

Foghorn Therapeutics Inc. director Ian F. Smith was granted 28,000 stock options at an exercise price of $4.08 per share. These options vest fully on the first anniversary of the grant date, contingent on his continued board service, and expire on June 23, 2036. This transaction

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Shareholders at Foghorn Therapeutics (NASDAQ: FHTX) approve pay and auditor

Foghorn Therapeutics Inc. shareholders approved key proposals at their 2026 Annual Meeting. They re-elected three Class III directors, ratified Deloitte & Touche LLP as the independent auditor for the 2026 fiscal year, and advisory-approved the compensation for named executive of

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 20:09
Source
Stock Titan
TradingKey Direct company coverage

Foghorn Therapeutics Inc. (FHTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Foghorn Therapeutics Inc. (FHTX) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends in the past five years and has no recorded stock split events. The page also includes current

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 19:10
Source
TradingKey
TradingKey Direct company coverage

Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article focuses on the revenue breakdown of Foghorn Therapeutics Inc. (FHTX) by business segments and regional contributions. However, it explicitly states that the relevant financial data for these categories has not been disclosed by the company yet. As a result, the artic

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 18:10
Source
TradingKey
TradingKey Direct company coverage

Foghorn Therapeutics Inc. (FHTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Foghorn Therapeutics Inc. (FHTX) currently holds an earnings forecast score of 9.00, placing it 14th in its industry, with an average analyst price target of $12.00, suggesting a significant upside. Ten analysts rate the stock as a "Strong Buy." The company's expected revenue for

Tone
Positive 71/100
Event
Earnings
Published
17 Jun 2026 13:10
Source
TradingKey